Drug Development for Rare Diseases Affecting Children is Increasing

While the number of drugs for rare diseases affecting children has grown, nearly 7,000 rare diseases still lack treatment options.

10:13 AM

Author | Beata Mostafavi

doctor with pill in hand

The number of treatments for rare diseases affecting children has increased, a new study suggests. But federal incentives intended to encourage drug development for rare conditions are being used more often to expand the use of existing drugs rather than for creating new ones.

Children are estimated to make up half of patients with rare diseases, which includes conditions that affect less than 200,000 Americans. Developing drugs for children with rare diseases is crucial to ensuring new treatment options, but it's not always profitable for drug manufacturers.

To motivate manufacturers to develop drugs to treat rare diseases, or "orphan drugs," federal policy provides incentives such as tax credits, grants for testing and a seven-year period of exclusivity during which competitors can't market an alternative version of the drug for the same disease.

MORE FROM THE LAB: Subscribe to our weekly newsletter

Of the 402 orphan drug indications approved through the U.S. Food and Drug Administration between 2010 and 2018, a third were specifically for children or for diseases that predominantly affected children, according to the findings published in Pediatrics.

But most of these pediatric orphan drug approvals were new uses of existing drugs, some of which are decades old and had already been approved to treat common diseases. Twenty received breakthrough designation, which is granted to drugs that hold particular promise for improving upon existing treatments.

"Our study reveals reason for optimism and reason for concern," says senior author Kao-Ping Chua, M.D., Ph.D., a pediatrician and researcher at Michigan Medicine C.S. Mott Children's Hospital and the Susan B. Meister Child Health Evaluation and Research Center.

"Many pediatric orphan indications may have represented breakthroughs for children with rare diseases. At the same time, most indications were not for new drugs, and some represented relatively minor expansions of use. Orphan drugs are costly to society, and it's important to make sure that these costs are justified by the amount of benefit to patients."

Like Podcasts? Add the Michigan Medicine News Break to your Alexa-enabled device or subscribe for updates on iTunesGoogle Play and Stitcher.

The researchers found that the 136 pediatric orphan drug approvals targeted 87 unique diseases, most commonly cystic fibrosis, acute lymphoblastic leukemia and immune disorder hereditary angioedema.

"Although the Orphan Drug Act has been effective in incentivizing drug development, our findings suggest that not all pediatric orphan indications hold the same value," says lead author Lauren Kimmel, a research assistant at the University of Michigan Medical School and CHEAR.

"Policymakers should ensure that resources are being used efficiently and effectively to stimulate development of new therapies for rare diseases that don't have any treatment options."

Paper Cited: "Pediatric Orphan Drug Indications: 2010–2018," Pediatrics. DOI: 10.1542/peds.2019-3128


More Articles About: Rounds CS Mott Children's Hospital Health Care Delivery, Policy and Economics Drug Discovery Pediatric Health Conditions Hospitals & Centers
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories doctor with head and neck in hands sitting down seeming depressed or stressed
Health Lab
More research is needed to support physicians' mental health, experts say
A pair of researchers who have studied physician mental health and stress call for more efforts to supports to prevent burnout and support wellbeing.
blurred front door exit with people walking through in blue see through doors
Health Lab
Medicare has a revolving door, study suggests
Medicare Advantage vs traditional Medicare is an annual Open Enrollment decision, and a new study looks at how many older adults revolve between the two.
man in orange shirt sitting in living room
Health Lab
Misinformation, AI & health: Poll reveals older adults’ worries
Health information generated by artificial intelligence, or created as misinformation, worries older adults, a poll shows.
surgeon dark room over surgery patient on hospital table
Health Lab
Women more likely than men to die after heart surgery complications
Despite having no greater chance of developing problems after high risk cardiovascular surgery, women are more likely than men to die from post-operative complications, a University of Michigan-led study suggests.
Blue umbrella with cross health insurance
Health Lab
Don’t choose health insurance for 2025 until you read this
Health insurance choices for 2025 have changed for Medicare, healthcare.gov and employer plans, and costs have too. An update on what’s most important to consider.
close up of yellow cells and blue greenish teal background
Health Lab
An ultrasound-activated hydrogel for steady, sustained drug delivery
Researchers have developed a new composite hydrogel capable of achieving sustained, zero-order drug release using ultrasound as a trigger.